A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay

Mohammed Desai, Bryony Dean Franklin, Alison H Holmes, Sarah Trust, Mike Richards, Ann Jacklin, Kathleen B Bamford, Mohammed Desai, Bryony Dean Franklin, Alison H Holmes, Sarah Trust, Mike Richards, Ann Jacklin, Kathleen B Bamford

Abstract

Background: Patients prescribed intravenous (IV) glycopeptides usually remain in hospital until completion of this treatment. Some of these patients could be discharged earlier if a switch to an oral antibiotic was made. This study was designed to identify the percentage of inpatients currently prescribed IV glycopeptides who could be discharged earlier if a switch to an oral agent was used, and to estimate the number of bed days that could be saved. We also aimed to identify the patient group(s) most likely to benefit, and to estimate the number of days of IV therapy that could be prevented in patients who remained in hospital.

Methods: Patients were included if they were prescribed an IV glycopeptide for 5 days or more. Predetermined IV to oral antibiotic switch criteria and discharge criteria were applied. A multiple logistic regression model was used to identify the characteristics of the patients most likely to be suitable for earlier discharge.

Results: Of 211 patients, 62 (29%) could have had a reduced length of stay if they were treated with a suitable oral antibiotic. This would have saved a total of 649 inpatient days (median 5 per patient; range 1-54). A further 31 patients (15%) could have switched to oral therapy as an inpatient thus avoiding IV line use. The patients most likely to be suitable for early discharge were those with skin and soft tissue infection, under the cardiology, cardiothoracic surgery, orthopaedics, general medical, plastic surgery and vascular specialities, with no high risk comorbidity and less than five other regularly prescribed drugs.

Conclusion: The need for glycopeptide therapy has a significant impact on length of stay. Effective targeting of oral antimicrobials could reduce the need for IV access, allow outpatient treatment and thus reduce the length of stay in patients with infections caused by antibiotic resistant gram-positive bacteria.

References

    1. Reacher MH, Shah A, Livermore DM, Wale MC, Graham C, Johnson AP, Heine H, Monnickendam MA, Barker KF, James D, George RC. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. British Medical Journal. 2000;320:213–6.
    1. Fergie JE, Pucell K. Infections in South Texas children. Pediatric Infectious Disease Journal. 2001;20:860–3. doi: 10.1097/00006454-200109000-00007.
    1. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, Leitch CD, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. Journal of the American Medical Association. 1998;279:593–8. doi: 10.1001/jama.279.8.593.
    1. Health Protection Agency . Surveillance of Surgical Site Infection in English Hospitals 1997–2002. Department of Health, London; 2003.
    1. Rojo D, Pinedo A, Clavijo E, Garcia-Rodriguez A, Garcia V. Analysis of risk factors associated with nosocomial bacteraemias. Journal of Hospital Infection. 1999;42:135–41. doi: 10.1053/jhin.1998.0543.
    1. Fernandez-Guerrero ML, Verdejo C, Azofra J, de Gorgolas M. Hospital-acquired infectious endocarditis not associated with cardiac surgery: an emerging problem. Clinical Infectious Diseases. 1995;20:16–23.
    1. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. American Journal of Medicine. 1987;83:1091–7. doi: 10.1016/0002-9343(87)90947-8.
    1. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin alone and with an aminoglycoside. Journal of Antimcrobial Chemotherapy. 1990;25:679–87.
    1. Parker SE, Nathwani D, O'Reilly D, Parkinson S, Davey PG. Evaluation of the impact of non-inpatient i.v. antibiotic treatment for acute infections on the hospital, primary care services and the patient. Journal of Antimicrobial Chemotherapy. 1998;42:373–80. doi: 10.1093/jac/42.3.373.
    1. Coello R, Charlett A, Ward V, Wilson J, Pearson A, Sedgwick J, Borriello P. Device-related sources of bacteraemia in English hospitals-opportunities for the prevention of hospital-acquired bacteraemia. Journal of Hospital Infection. 2003;53:46–57. doi: 10.1053/jhin.2002.1349.
    1. Chee HP, Dean B. Evaluation of an antibiotic 'IV to oral' switch on an orthopaedics ward. Pharmacy World and Science. 2002;24:A48.
    1. Laing RBS, Mackenzie AR, Shaw H, Gould IM, Douglas JG. The effect of intravenous-to-oral-switch guidelines on the use of parenteral antimicrobials in medical wards. Journal of Antimicrobial Chemotherapy. 1998;42:107–111. doi: 10.1093/jac/42.1.107.
    1. Sevinc F, Prins JM, Koopmans RP, Langendijk PN, Bossuyt PM, Dankert J, Speelman P. Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital. Journal of Antimicrobial Chemotherapy. 1999;43:601–606. doi: 10.1093/jac/43.4.601.
    1. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. Journal of Antimicrobial Chemotherapy. 2004;53:335–44. doi: 10.1093/jac/dkh088.
    1. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderkind RG. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003;124:1789–97. doi: 10.1378/chest.124.5.1789.
    1. Auckland C, Teare L, Cooke F, Kaufmann ME, Warner M, Jones G, Bamford K, Ayles H, Johnson AP. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. Journal of Antimicrobial Chemotherapy. 2002;50:742–746. doi: 10.1093/jac/dkf246.
    1. Dean B, Lawson W, Jacklin A, Tom Rogers, Berge Azadian, Alison Holmes. The use of serial point prevalence studies to investigate antiinfective prescribing. International Journal of Pharmacy Practice. 2003;10:121–5.
    1. Parodi S, Rhew DC, Goetz MB. Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin-resistant staphylococcal species infections. Journal of Managed Care Pharmacy. 2003;9:317–26.
    1. Nathwani D, Barlow GD, Ajdukiewicz K, Gray K, Morrison J, Clift B, Frances AJ, Davey P. Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy. Journal of Antimicrobial Chemotherapy. 2003;51:391–6. doi: 10.1093/jac/dkg061.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever